Table 1:
Patient characteristics
| Variable | ICI (n=69) | Non-ICI (n=37) |
|---|---|---|
| Age, yr | 65 (55–71) | 63 (58–68.4) |
| Female (%) | 11 (15.9) | 10 (27.0) |
| Transplant type, n (%) | ||
| LUKTx | 16 (23.2) | 6 (16.2) |
| LRKTx | 24 (34.8) | 15 (40.5) |
| DDKTx | 27 (39.1) | 12 (32.4) |
| Unknown | 2 (2.9) | 4 (10.8) |
| Baseline Cr, mg/dl | 1.34 (1.1– 1.72) | 1.2 (0.96–1.65) |
| Cancer type, n (%) | ||
| cSCC | 24 (34.8) | 23 (62.2) |
| Melanoma | 22 (31.9) | 14 (37.8) |
| NSCLC | 8 (11.6) | |
| Merkel Cell Carcinoma | 4 (5.8) | |
| RCC | 3 (4.3) | |
| Bladder | 2 (2.9) | |
| Others | 6 (8.7) | |
| Other cancer-directed therapy, n (%) | 41 (59.4) | 27 (73) |
| Transplant to ICI, yr | 9.33 (4.1–15.6) | NA |
| ICI, n (%) | NA | |
| Pembrolizumab | 29 (42.0) | |
| Nivolumab | 11 (15.9) | |
| Cemiplimab | 10 (14.5) | |
| Atezolizumab | 3 (4.3) | |
| Avelumab | 3 (4.3) | |
| Ipilimumab | 2 (2.9) | |
| PD-1/CTLA-4 combination | 11 (15.9) | |
| irAE, n (%), apart from rejection | NA | |
| None | 52 (75.4) | |
| At least one | 17 (24.6) | |
| Dermatitis | 5 (25.0) | |
| Encephalopathy | 4 (20.0) | |
| Hepatitis | 3 (15.0) | |
| Endocrinopathy | 3 (15.0) | |
| Colitis | 1 (5.0) | |
| Others | 4 (20.0) | |
| Tumor response, n (%) | ||
| CR | 5 (7.2) | 2 (5.4) |
| PR | 15 (21.7) | 2 (5.4) |
| SD | 11 (15.9) | 5 (13.5) |
| PD | 34 (49.3) | 28 (75.7) |
| Unknown | 4 (5.8) | 0 (0) |
| Follow-up, months | 12 (6.3–22.3) | 9.7 (4.2–21.4) |
Data are shown as median (IQR) and n (%). IQR; interquartile range, LUKTx; living-unrelated kidney transplant, LRKTx; living-related kidney transplant, DDKTx; deceased kidney transplant, Cr; creatinine, cSCC; cutaneous squamous cell carcinoma, NSCLC; non-small cell lung carcinoma, RCC; renal cell carcinoma, ICI; immune checkpoint inhibitor, PD-1; programmed cell death protein 1, CTLA-4; cytotoxic T-lymphocyte-associated protein 4, CR; complete response, PR; partial response, SD; stable disease, PD; progressive disease, irAE; immune-related adverse event. Other cancer-directed therapy includes chemotherapy and molecular-targeted therapy except for ICI.